Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Martha Neagu"'
Autor:
J. Bryan Iorgulescu, Neil Ruthen, Ryuhjin Ahn, Eleni Panagioti, Prafulla C. Gokhale, Martha Neagu, Maria C. Speranza, Benjamin K. Eschle, Kara M. Soroko, Raziye Piranlioglu, Meenal Datta, Shanmugarajan Krishnan, Kathleen B. Yates, Gregory J. Baker, Rakesh K. Jain, Mario L. Suvà, Donna Neuberg, Forest M. White, E. Antonio Chiocca, Gordon J. Freeman, Arlene H. Sharpe, Catherine J. Wu, David A. Reardon
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe GL261 and CT2A syngeneic tumor lines are frequently used as immunocompetent orthotopic mouse models of human glioblastoma (huGBM) but demonstrate distinct differences in their responses to immunotherapy.MethodsTo decipher the cell-intri
Externí odkaz:
https://doaj.org/article/0d4ef411871943b490bc6d2c4f558fb2
Autor:
Bryan Iorgulescu, Neil Ruthen, Ryuhjin Ahn, Eleni Panagioti, Prafulla Gokhale, Martha Neagu, Maria Speranza, Benjamin Eschle, Kara Soroko, Raziye Piranlioglu, Meenal Datta, Shanmugarajan Krishnan, Kathleen Yates, Gregory Baker, Rakesh Jain, Mario Suva, Donna Neuberg, Forest White, E. Chiocca, Gordon Freeman, Arlene Sharpe, Catherine Wu, David Reardon
Publikováno v:
Cancer Research. 83:2990-2990
The GL261-luc2 and CT2A-luc syngeneic tumor lines are frequently used as immunocompetent orthotopic mouse models of human glioblastoma (huGBM), but demonstrate distinct differences in response to immune checkpoint blockade. Whereas GL261-luc2 is read
Autor:
Meenal Datta, Sampurna Chatterjee, Elizabeth Perez, Simon Gritsch, Sylvie Roberge, Mark Duquette, Ivy Chen, Kamila Naxerova, Ashwin Kumar, Mitrajit Ghosh, Kyrre Emblem, Rosa Ng, William Ho, Pragya Kumar, Shanmugarajan Krishnan, Xinyue Dong, Maria Speranza, Martha Neagu, David A Reardon, Arlene Sharpe, Gordon Freeman, Mario Suva, Lei Xu, Rakesh Jain
Publikováno v:
Neuro-Oncology. 24:vii285-vii285
Immune checkpoint blockers (ICBs) have revolutionized the treatment of some solid cancers but have failed to benefit the majority of glioblastoma (GBM) patients. Two reasons underlying limited ICB benefit are: 1) immune-related adverse events, and 2)
Autor:
Shimizu, Toshio, Powderly, John, Sharma, Manish R., Guan, Xiaowen, Vasilopoulos, Athanasios, Li, Martha, Li, Rui, Cunningham, Alexis, Reilly, Regina, Morrison-Thiele, Gladys, Freise, Kevin, Aristide, Martha Neagu, Camidge, D. Ross
Publikováno v:
In Annals of Oncology November 2023 34 Supplement 3:S1397-S1397
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Pediatric Research. 43:315-315
The stress response is initiated in energy deprived renal epithelia coordinate with disruption of cell architecture including loss of Na/K-ATPase attachment to the cytoskeleton; HSP-72 elaboration coincides with cellular restitution. Assessing putati